- Wanhua Chemical reported a net income of 6.12 billion yuan for the first half of the year.
- The company’s total revenue amounted to 90.90 billion yuan during this period.
- Revenue from the polyurethanes series was 36.89 billion yuan.
- The petrochemical series contributed 34.93 billion yuan in revenue.
- Revenue from the fine chemicals and new materials series reached 15.63 billion yuan.
- Earnings per Share (EPS) for Wanhua Chemical stood at 1.95 yuan.
- Analysts’ ratings include 23 buy recommendations, 3 holds, and no sell recommendations.
A look at Wanhua Chemical Group Co A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Wanhua Chemical Group Co A appears to have a positive long-term outlook. With high scores in Value and Dividend, the company shows strength in its financial health and ability to provide returns to investors. The Growth and Resilience scores, although not as high, indicate a solid foundation for future development and ability to weather market challenges. However, the Momentum score is relatively lower, suggesting a slower pace in market performance.
Wanhua Chemical Group Co A, known for its development, manufacturing, and marketing of isocyanate, polyurethane, and other chemical products, seems to be well-positioned for sustainable growth and steady dividend payments to shareholders. While there may be room for improvement in generating market momentum, the company’s strong value, dividend payouts, and overall resilience paint a promising picture for its long-term prospects in the chemical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
